Browse AMR Mutations
Explore antimicrobial resistance mutations from the literature
Explore antimicrobial resistance mutations from the literature
Overview
Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages.
Mutation in gyrA at position 90 (A90V) confers resistance to fluoroquinolones.
Evaluation of MTBDRplus and MTBDRsl in Detecting Drug-Resistant Tuberculosis in a Chinese Population.
Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa.
Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis.
detected by MTBDRsl assay
Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase.
Mutations in the quinolone resistance-determining regions (QRDR) of GyrA and GyrB.
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Previously reported
GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples.
Mutations in gyrA were associated with resistance to fluoroquinolones.
Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China.
Rapid identification of extensively and extremely drug resistant tuberculosis from multidrug resistant strains; using PCR-RFLP and PCR-SSCP.
Antimicrobial Resistance Mechanisms in Mycobacterium tuberculosis: Role of Efflux Pumps and Mutations
Impact of gyrB and eis Mutations in Improving Detection of Second-Line-Drug Resistance among Mycobacterium tuberculosis Isolates from Georgia.
most common mutation
The DnaK Chaperone System Buffers the Fitness Cost of Antibiotic Resistance Mutations in Mycobacteria.
Fluoroquinolone resistance-conferring mutations in gyrA show no fitness defect in the absence of DnaJ1 or DnaJ2.
Computational modeling and bioinformatic analyses of functional mutations in drug target genes in Mycobacterium tuberculosis.
Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
Whole-genome sequencing of Mycobacterium tuberculosis for prediction of drug resistance.
Mutations in gyrA were associated with ofloxacin resistance.
Transmission of multidrug-resistant tuberculosis in Jiangxi, China, and associated risk factors.
Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Mutations in gyrA were associated with increased MICs for fluoroquinolones.
Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates.
mutations detected in 7 strains
Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria.
The mutation was identified in moxifloxacin-resistant colonies.
Rapid diagnosis of extensively drug-resistant tuberculosis by use of a reverse line blot hybridization assay.
Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis.
associated with fluoroquinolone resistance
Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment.
Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.
Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa.
Drug-resistant tuberculosis in Central Mozambique: the role of a rapid genotypic susceptibility testing.
First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant Mycobacterium tuberculosis in Saudi Arabia.
Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.
GyrA mutations are associated with fluoroquinolone resistance.
Molecular characteristics of ofloxacin mono-resistant Mycobacterium tuberculosis isolates from new and previously treated tuberculosis patients.
Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study.
Mutations in gyrA and gyrB are associated with fluoroquinolone resistance in Mycobacterium tuberculosis.
Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum.
Whole-genome sequencing reveals transmission pattern and drug resistance of Mycobacterium tuberculosis intra- or inter-hosts.
Molecular characterization of mutations associated with resistance to second line drugs in Mycobacterium tuberculosis patients from Casablanca, Morocco.
Increasing prevalence of resistance to second-line drugs among multidrug-resistant Mycobacterium tuberculosis isolates in Kuwait.
Whole genome analysis of extensively drug resistant Mycobacterium tuberculosis strains in Peru.
Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova.
Multiple gyrA mutations (D94G, D94A, A90V) confer resistance to fluoroquinolones.
Genomic Profiling of Mycobacterium tuberculosis Strains, Myanmar.
Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial.
Analysis on Drug-Resistance-Associated Mutations among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China.
A modified decision tree approach to improve the prediction and mutation discovery for drug resistance in Mycobacterium tuberculosis.
Application of Amplicon-Based Targeted NGS Technology for Diagnosis of Drug-Resistant Tuberculosis Using FFPE Specimens.
high-confidence mutation
Mycobacterium tuberculosis Lineages Associated with Mutations and Drug Resistance in Isolates from India.
Molecular Epidemiology and Polymorphism Analysis in Drug-Resistant Genes in M. tuberculosis Clinical Isolates from Western and Northern India.
variable codons
Whole genome sequencing analysis of Mycobacterium tuberculosis reveals circulating strain types and drug-resistance mutations in the Philippines.
Common mutations underlying fluoroquinolone resistance.
Genetic diversity and transmission pattern of multidrug-resistant tuberculosis based on whole-genome sequencing in Wuhan, China.
Clinical characteristics and genomic epidemiological survey of tuberculosis in Wuzhou, China, 2022.
Identification and quantification of gyrA variants in fluoroquinolone-resistant Mycobacterium tuberculosis in a MeltArray reaction.
All mutations are in the quinolone resistance-determining region (QRDR) of gyrA.
Genomic characterization of multidrug-resistant tuberculosis in Shanghai, China: antibiotic resistance, virulence and transmission.
Whole genome sequencing-based detection of extensively drug-resistant tuberculosis from Ethiopia.
Genomic characterization of XDR Mycobacterium tuberculosis isolates in Argentina (2006-2015).
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.
Mutations in gyrA and gyrB were associated with quinolone resistance or hypersusceptibility.
Mycobacterium tuberculosis gyrA conferring resistance to fluoroquinolones; CARD accession: CARD:3003295
Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
The A90V mutation in gyrA was found to be associated with high-level fluoroquinolone resistance.
Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009.
The S95T mutation in gyrA was a natural polymorphism and not considered a resistance mechanism.
Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis.
Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing.
Triplex real-time PCR melting curve analysis for detecting Mycobacterium tuberculosis mutations associated with resistance to second-line drugs in a single reaction.
Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis.
Diagnostic Performance of the GenoType MTBDRplus and MTBDRsl Assays to Identify Tuberculosis Drug Resistance in Eastern China.
Five-year microevolution of a multidrug-resistant Mycobacterium tuberculosis strain within a patient with inadequate compliance to treatment.
Whole genome sequencing of clinical samples reveals extensively drug resistant tuberculosis (XDR TB) strains from the Beijing lineage in Nigeria, West Africa.
Correlation of gyr Mutations with the Minimum Inhibitory Concentrations of Fluoroquinolones among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Bangladesh.
Mutations in the gyrA gene are associated with fluoroquinolone resistance in MDR-TB isolates.
Performance of GenoType MTBDRsl assay for detection of second-line drugs and ethambutol resistance directly from sputum specimens of MDR-TB patients in Bangladesh.
Use of Whole-Genome Sequencing to Predict Mycobacterium tuberculosis Complex Drug Resistance from Early Positive Liquid Cultures.
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis.
Whole genomic analysis uncovers high genetic diversity of rifampicin-resistant Mycobacterium tuberculosis strains in Botswana.
Evaluation of the Xpert MTB/XDR test for detection of isoniazid, fluoroquinolones, and second-line injectable drugs resistance to Mycobacterium tuberculosis-Anhui Province, China.
A novel one-tube nested fluorescence melting curve analysis for rapid detection of drug-resistant Mycobacterium tuberculosis.
All mutations were confirmed by DNA sequencing.
Fluoroquinolone and Second-Line Injectable Resistance Among Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates: A Molecular Study from a High-Burden Setting.
mutations in gyrA are associated with fluoroquinolone resistance
Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis.
The A90V mutation in gyrA was associated with high-level resistance to fluoroquinolones in XDR isolates.
Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia.
associated with ofloxacin resistance
Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.
Mutations in gyrA are associated with fluoroquinolone resistance in Mycobacterium tuberculosis.
Added value of whole-genome sequencing for management of highly drug-resistant TB.
Conflicting evidence or evidence suggesting a weak association with a drug-resistant phenotype
Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.
Mutations in gyrA are associated with fluoroquinolone resistance.
Whole genome sequencing based characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from Pakistan.
Mutations in the gyrA gene associated with fluoroquinolone resistance
Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases.
Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.
Mutations in gyrA are associated with fluoroquinolone resistance in Mycobacterium tuberculosis.
Comparative Evaluation of Sloppy Molecular Beacon and Dual-Labeled Probe Melting Temperature Assays to Identify Mutations in Mycobacterium tuberculosis Resulting in Rifampin, Fluoroquinolone and Aminoglycoside Resistance.
Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
Mutations in gyrA QRDR correlate with increased MICs for fluoroquinolones.
Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
Mutations in gyrA were associated with OFX resistance.
Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRsl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectables Drugs: a Multicenter Study.
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations.
Mutations in gyrA were correlated with levofloxacin resistance.
Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
MTBDRplus and MTBDRsl Assays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis.
Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.
Mutations in GyrA lead to fluoroquinolone resistance by disrupting the water-metal ion bridge.
Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains.
The Genetic Background Modulates the Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis.
Most prevalent in high-frequency OFX-R strains.
Prevalence, risk and genetic characteristics of drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China.
Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
Mutation in GyrA (A90V) confers resistance to fluoroquinolones.
Pre-detection history of extensively drug-resistant tuberculosis in KwaZulu-Natal, South Africa.
Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan.
Detection of Second Line Drug Resistance among Drug Resistant Mycobacterium Tuberculosis Isolates in Botswana.
Most common fluoroquinolone resistance-conferring mutation detected
Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China.
Novel mutations detected in gyrA and gyrB genes.
A retrospective genomic analysis of drug-resistant strains of M. tuberculosis in a high-burden setting, with an emphasis on comparative diagnostics and reactivation and reinfection status.
Genomic Analysis of Mycobacterium tuberculosis Isolates and Construction of a Beijing Lineage Reference Genome.
The G88C mutation in gyrA was found in TCDC4 and TCDC10.
Molecular characterization of pre-extensive drug resistant Mycobacterium tuberculosis in Northeast Brazil.
Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.
Mutations in gyrA are associated with fluoroquinolone resistance.
Performance of the MTBDRsl assay in Georgia.
Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations.
Evaluation of the AID TB resistance line probe assay for rapid detection of genetic alterations associated with drug resistance in Mycobacterium tuberculosis strains.
Pyrosequencing for rapid detection of tuberculosis resistance in clinical isolates and sputum samples from re-treatment pulmonary tuberculosis patients.
The structural modeling of the interaction between levofloxacin and the Mycobacterium tuberculosis gyrase catalytic site sheds light on the mechanisms of fluoroquinolones resistant tuberculosis in Colombian clinical isolates.
Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
Mutations in gyrA gene associated with fluoroquinolone resistance.
Performance of an Xpert-based diagnostic algorithm for the rapid detection of drug-resistant tuberculosis among high-risk populations in a low-incidence setting.
Whole-Genome Sequencing of Drug-Resistant Mycobacterium tuberculosis Strains, Tunisia, 2012-2016.
Genetic Characterization of Second-Line Drug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis from the Northern Region of India.
Mutations in the QRDR region of the gyrA gene are associated with fluoroquinolone resistance
In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.
Mutations in gyrA associated with fluoroquinolone resistance
New insights on tuberculosis transmission dynamics and drug susceptibility profiles among the prison population in Southern Brazil based on whole-genome sequencing.
Evolution and epidemic success of Mycobacterium tuberculosis in eastern China: evidence from a prospective study.
Mutations in gyrA are associated with fluoroquinolone resistance.
Rapid detection of fluoroquinolone resistance in Mycobacterium tuberculosis using a novel multienzyme isothermal rapid assay.
Mutations in codons 90 and 94 of gyrA are associated with fluoroquinolone resistance.
Machine learning and phylogenetic analysis allow for predicting antibiotic resistance in M. tuberculosis.
associated with resistance to fluoroquinolones
Molecular Analysis of Anti-Tuberculosis Drug Resistance of Mycobacterium tuberculosis Isolated in the Republic of Korea.
Analysis of Drug-Resistance Characteristics and Genetic Diversity of Multidrug-Resistant Tuberculosis Based on Whole-Genome Sequencing on the Hainan Island, China.
Insight into the drug-resistant characteristics and genetic diversity of multidrug-resistant Mycobacterium tuberculosis in China.
Mixed infections in genotypic drug-resistant Mycobacterium tuberculosis.
Prolonged survival of a patient with active MDR-TB HIV co-morbidity: insights from a Mycobacterium tuberculosis strain with a unique genomic deletion.
A precision overview of genomic resistance screening in Ecuadorian isolates of Mycobacterium tuberculosis using web-based bioinformatics tools.
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.
Mutations in gyrA codons 90, 91, and 94 are commonly associated with fluoroquinolone resistance.
High-resolution melting analysis for the rapid detection of fluoroquinolone and streptomycin resistance in Mycobacterium tuberculosis.
Mutations in gyrA were associated with fluoroquinolone resistance.
Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis.
Mutations in gyrA gene confer resistance to fluoroquinolones.
Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays.
Resistance of Mycobacterium tuberculosis to antibiotics in Lao PDR: first multicentric study conducted in 3 hospitals.
The A90V mutation in gyrA is associated with fluoroquinolone resistance.
Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa.
Primary multidrug-resistant Mycobacterium tuberculosis in 2 regions, Eastern Siberia, Russian Federation.
Fluoroquinolones, gyrA Not performed
Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis.
Mutations in gyrA confer resistance to fluoroquinolones
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Mutations in gyrA contribute to quinolone resistance in Mycobacterium tuberculosis.
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
This mutation does not confer resistance and was excluded from the analysis.
Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.
Heterozygous mutations were observed in 4/27 (14.8%) mutations.
In Vitro Activity and MIC of Sitafloxacin against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis Isolated in Thailand.
Double mutations of Ala90Val and Asp94Ala were found in strains with a MIC of 1.0 μg/ml.
Multi-clonal evolution of multi-drug-resistant/extensively drug-resistant Mycobacterium tuberculosis in a high-prevalence setting of Papua New Guinea for over three decades.
Mutations promoted from gene entry 'gyrA' (model emitted mutations_found inside genes).
Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones.
Accuracy of whole genome sequencing versus phenotypic (MGIT) and commercial molecular tests for detection of drug-resistant Mycobacterium tuberculosis isolated from patients in Brazil and Mozambique.
Most common mutation related to fluoroquinolone resistance in all isolates
Phylogenomic assessment of drug-resistant Mycobacterium tuberculosis strains from Beira, Mozambique.
Multidrug- and Extensively Drug-Resistant Mycobacterium tuberculosis Beijing Clades, Ukraine, 2015.
Mutations promoted from gene entry 'gyrA' (model emitted mutations_found inside genes).
Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance.
Mutations in gyrA and gyrB are the most frequent mechanism of fluoroquinolone resistance.
Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients.
Mutations in gyrA are associated with high-level resistance to fluoroquinolones.
Genotype analysis of ofloxacin-resistant multidrug-resistant Mycobacterium tuberculosis isolates in a multicentered study from India.
Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.
Mutation at codon 90 (Ala→Val) was found in some isolates.
Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study.
Mutation associated with fluoroquinolone resistance.
A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics.
mutations in gyrA are associated with fluoroquinolone resistance
Mycobacterium tuberculosis gyrA conferring resistance to fluoroquinolones; CARD accession: CARD:3003295
High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Mutations in gyrA are associated with fluoroquinolone resistance.
Predicting antibiotic resistance in complex protein targets using alchemical free energy methods.
Resistant to moxifloxacin
Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: A 10-year retrospective study.
Mutations in gyrA were associated with fluoroquinolone resistance in Mycobacterium tuberculosis.
Whole Genome Sequencing of Mycobacterium tuberculosis under routine conditions in a high-burden area of multidrug-resistant tuberculosis in Peru.
Targeted next-generation sequencing of Mycobacterium tuberculosis from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh.
Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.
Mycobacterium tuberculosis gyrA conferring resistance to fluoroquinolones; CARD accession: CARD:3003295
Mycobacterium tuberculosis gyrA conferring resistance to fluoroquinolones; CARD accession: CARD:3003295
Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis.
Mycobacterium tuberculosis gyrA conferring resistance to fluoroquinolones; CARD accession: CARD:3003295
Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea.
Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance.
Detection of streptomycin and quinolone resistance in Mycobacterium tuberculosis by a low-density DNA array.
Evaluation of genotype MTBDRsl assay to detect drug resistance associated with fluoroquinolones, aminoglycosides and ethambutol on clinical sediments.
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing.
Tuberculosis drug resistance mutation database.
No comments yet. Be the first to comment!
© 2026 ResLit. Data sourced from PubMed literature analysis.
Built for antimicrobial resistance research